Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 11Phase 1 7Phase 1/2 5Phase NA 4Phase 2/3 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 24Head and Neck Neoplasms 21Lung Neoplasms 19Neoplasms 18Stomach Neoplasms 15Urinary Bladder Neoplasms 14Uterine Cervical Neoplasms 11Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Esophageal Neoplasms 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Biliary Tract Neoplasms 10Carcinoma, Transitional Cell 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Oropharyngeal Neoplasms 7Mesothelioma, Malignant 7Melanoma 7Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Recurrence 5Nasopharyngeal Carcinoma 5Mesothelioma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Nasopharyngeal Neoplasms 4Mouth Neoplasms 4

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Cisplatin × Clear all
NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
202 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
100 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting
51 enrolled

Carcinoma, Neoplasms, Recurrence

NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡